Shares of Avinger Inc. (NASDAQ:AVGR) hit a new 52-week low during trading on Friday . The stock traded as low as $6.16 and last traded at $6.19, with a volume of 113,495 shares changing hands. The stock had previously closed at $6.27.

Several analysts have commented on AVGR shares. Zacks Investment Research lowered Avinger from a “hold” rating to a “sell” rating in a report on Monday, May 9th. Canaccord Genuity reissued a “buy” rating and issued a $20.00 price objective on shares of Avinger in a report on Wednesday, March 30th. Finally, BTIG Research reissued a “buy” rating and issued a $18.00 price objective on shares of Avinger in a report on Friday, July 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $18.75.

The firm’s 50-day moving average is $10.39 and its 200-day moving average is $12.48. The stock’s market cap is $78.32 million.

Avinger (NASDAQ:AVGR) last posted its earnings results on Wednesday, May 4th. The medical device company reported ($1.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.11. Analysts expect that Avinger Inc. will post ($4.26) EPS for the current year.

In other Avinger news, Director Donald A. Lucas sold 9,309 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $12.58, for a total transaction of $117,107.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Himanshu Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $13.40, for a total value of $134,000.00. Following the sale, the insider now directly owns 87,220 shares of the company’s stock, valued at $1,168,748. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Avinger stock. Paradigm Capital Management Inc. NY increased its stake in shares of Avinger Inc. (NASDAQ:AVGR) by 41.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 367,056 shares of the medical device company’s stock after buying an additional 108,222 shares during the period. Paradigm Capital Management Inc. NY owned approximately 2.91% of Avinger worth $8,336,000 at the end of the most recent quarter.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.